The North America Nuclear Medicine Market was valued at $3069.2 Million in 2025 and projected to reach to $5801.6 Million by 2030, representing a compound annual growth rate of 13.6%. North America's nuclear medicine market is poised for sustained expansion through 2030, driven by increasing prevalence of chronic diseases, aging demographics, and growing demand for precise diagnostic imaging.
North America's nuclear medicine market is valued at $3,069.2 million in 2025, with a robust CAGR of 13.6%, projected to reach $5,801.6 million by 2030, demonstrating strong regional demand for advanced diagnostic imaging.
The region benefits from state-of-the-art medical facilities, cutting-edge diagnostic imaging technology adoption, and well-established clinical protocols that support widespread nuclear medicine utilization across hospitals and imaging centers.
Favorable reimbursement policies from Medicare, Medicaid, and private insurers in the US and Canada create a supportive environment for nuclear medicine procedures, driving accessibility and market expansion.
Significant investments in medical research and development across North America fuel innovation in radiopharmaceuticals, imaging equipment, and diagnostic protocols, positioning the region as a leader in nuclear medicine advancement.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | THERAPEUTIC NUCLEAR MEDICINE (Type) |
| Forecast Period | 2025–2039 |
| Growth Rate | CAGR of 15.1% from 2025 to 2039 |
| Largest Segment | DIAGNOSTIC PROCEDURES (Procedure) |
| Market Size Base Year (Billions) | ~USD 10.4 (2025) |
| Revenue Forecast (Billions) | ~USD 21.01 (2039) |
| Segments Covered | Type, Application, Procedure, End User |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | SPECT,PET,Beta Emitters, |
| CARL ZEISS AG | Germany | Public Company | PET (F-18),SPECT (Tc-99m), |
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | SPECT,PET,Brachytherapy, |
| BRUKER CORPORATION | United States | Public Company | PET,SPECT,Beta Emitters, |
| SHIMADZU CORPORATION | Japan | Public Company | PET (F-18),SPECT (Tc-99m),Alpha Emitters, |
| VARIAN MEDICAL SYSTEMS, INC | United States | Private Company | Brachytherapy,Linear Accelerators,Software Solutions, |
| LEONI AG | Germany | Private Company | PET Systems,SPECT Systems,Beta Emitters, |
| PFIZER | United States | Public Company | PET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m), |
| ELEKTA AB | Sweden | Public Company | Brachytherapy,Linear Accelerators,Stereotactic Radiosurgery, |
| NOVARTIS AG | Switzerland | Public Company | Beta Emitters,SPECT,Alpha Emitters, |
| LANTHEUS HOLDINGS, INC. | United States | Public Company | PET,SPECT,Beta Emitters, |
| GE HEALTHCARE | United States | Public Company | SPECT,PET,Brachytherapy, |
| TELIX PHARMACEUTICALS LIMITED | Australia | Public Company | PET Imaging,Therapeutics,Manufacturing Solutions, |
| SIEMENS HEALTHINEERS | Germany | Public Company | PET,SPECT,Beta Emitters, |
| CHINA ISOTOPE & RADIATION CORPORATION | China | Public Company | SPECT,PET,Beta Emitters, |
| BAYER AG | Germany | Public Company | SPECT,PET,Alpha Emitters, |
| CARDINAL HEALTH | United States | Public Company | SPECT,PET,Beta Emitters, |
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.
Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.
Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.
Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.
Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.
Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.
Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.
Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.
Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.
Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.
GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.
Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.
China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.
Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.
Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.
| Country | 2025 size (native) |
|---|---|
| US | USD 9155.5 Million |
| Canada | USD 402.7 Million |
North America's nuclear medicine market is projected to reach $5,801.6 million by 2030, up from $3,069.2 million in 2025.
North America's nuclear medicine market is expected to grow at a compound annual growth rate of 13.6% between 2025 and 2030.
North America's growth is driven by advanced healthcare infrastructure, aging population demographics, rising cancer incidence, strong reimbursement frameworks, and FDA-supported innovation in radiopharmaceuticals.
PET/CT and SPECT imaging are the dominant modalities in North America, supported by widespread clinical adoption and strong healthcare provider investment.
North America's FDA regulatory framework promotes innovation in radiopharmaceuticals and imaging equipment, accelerating market growth and clinical adoption of advanced nuclear medicine technologies.
This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.
Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
Report Metric |
Details |
|
Siemens Healthineers |
Sr.Sales Manager |
|
Curium |
General Manager |
|
Cardinal Health |
Product Sales Specialist |
Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.
Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.
MarketsandMarkets offers the following customizations for this market report:
Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report